The safety of anidulafungin

Expert Opinion on Drug Safety

Volumn 5, Issue 6, 2006, Pages 751-758

  Vazquez, José A ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anidulafungin; Echinocandin; Fungi; Glucan synthase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBAMAZEPINE; CASPOFUNGIN; CREATININE; CYCLOSPORIN A; DEXAMETHASONE; FLUCONAZOLE; HEMOGLOBIN; METRONIDAZOLE; MICAFUNGIN; NIFEDIPINE; PHENYTOIN; PLACEBO; POTASSIUM; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALTERNARIA; ANAPHYLAXIS; ANEMIA; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; CROSS RESISTANCE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOCARDITIS; ESOPHAGUS CANDIDIASIS; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; LEUKOPENIA; LIVER DYSFUNCTION; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PHLEBITIS; REVIEW; SCEDOSPORIUM; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; THERAPY RESISTANCE; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; HUMANS; PEPTIDES, CYCLIC;

EID: 33750553597     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.6.751     Document Type: Review

References (48)

1. PFALLER MA: Epidemiology of candidiasis. J. Hosp. Infect. (1995) 30(Suppl.):329-338.
2. DENNING DW: Invasive aspergillosis. Clin. Infect. Dis. (1998) 26:781-803.
3. HAJJEH RA, SOFAIR AN, HARRISON LH et al.: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. (2004) 42:1519-1527.
4. TRICK WE, FRIDKIN SK, EDWARDS JR et al.: for the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. (2002) 35:627-630.
5. OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida Isolates in the United States. Antimicrob. Agent Chemother. (2003) 47:3149-3154.
6. BATES DW, SU L, YU DT et al.: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. (2001) 32:686-693.
7. WINGARD JR, KUBILIS P, LEE L et al.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. (1999) 29:1402-1407.
8. FROMTLING RA: Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev. (1988) 1:187-217.
9. DENNING DW: Echinocandin antifungal drugs. Lancet (2003) 362:1142-1151.
10. MORRISON VA: The role of caspofungin and the echinocandins in the antifungal armamentarium. Curr. Opin. Investig. Drugs (2002) 3:1432-1436.
11. NO AUTHORS LISTED: Eraxis (anidulafungin), Package Insert. New York, NY, Pfizer, Inc. (2006).
12. CHAVEZ M, BERNAL S, VALVERDE A et al.: In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J. Antimicrob. Chemother. (1999) 44:697-700.
13. ODABASI Z, PAETZNICK VL, RODRIGUEZ JR, CHEN E, OSTROSKY-ZEICHNER L: In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agent Chemother. (2004) 48:1912-1915.
14. PFALLER MA, BOYKEN L, HOLLIS RJ, MESSER SA, TENDOLKAR S, DIEKEMA DJ: In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. (2005) 43:5425-5427.
15. ZHANEL GG, KARLOWSKY JA, HARDING GAJ et al.: In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. (1997) 41:863-865.
16. SERRANO MC, VALVERDE-CONDE A, CHAVEZ M et al.: In-vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn. Microbiol. Infect. Dis. (2003) 45:131-135.
17. ESPINEL-INGROFF A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003 20:121-136.
18. MOUDGAL V, LITTLE T, BOIKOV D, VAZQUEZ JA: Multi-echinocandin and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. (2005) 49:267-269.
19. HERNANDEZ S, LOPEZ-RIBOT JL, NAJVAR LK, MCCARTHY DI, BOCANEGRA R, GRAYBILL JR: Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. (2004) 48:1382-1383.
20. PARK S, KELLY R, KAHN JN et al.: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. (2005) 49:3264-3273.
21. HAKKI M, STAAB JF, MARR KA: Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. (2006) 50:2522-2524.
22. DOWELL JA, PU F, LEE J et al.: A clinical mass balance study of anidulafungin showing complete fecal elimination. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology. Chicago, USA (2003) 32:Abstract 1576.
23. HOBAN D, BALKO T, SAUNDERS D et al.: Influence of human serum on Candida spp. Susceptibility to LU-303366. In: Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (1998) 38:453, J-9.
24. STOGNIEW M, PU F, HENKEL T, DOWELL J: Anidulafungin biotransformation in humans is by degradation not metabolism. In: Program and abstracts of the 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, UK (2003):Abstract P-1223.
25. DOWELL JA, KNEBEL W, LUDDEN T et al.: Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. (2004) 44:590-598.
26. DOWELL JA, STOGNIEW M, KRAUSE D, HENKEL T, WESTON IE: Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J. Clin. Pharmacol. (2005) 45(2):227-233.
27. NO AUTHORS LISTED: Cancidas (caspofungin) Package Insert. Whitehouse Station, NJ: Merck & Co., Inc. (2005).
28. MARR KA, HACHEM R, PAPANICOLAOU G et al.: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis. (2004) 6:110-116.
29. STOGNIEW M, DOWELL JA, KRAUSE D, HENKEL T: Population pharmacokinetics (PK) confirms absence of anidulafungin drug-drug interactions. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (2004). Poster 1035.
30. STONE JA, MIGOYA E, HICKEY L et al.: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. (2004) 48:4306-4314.
31. HERBRECHT R, GRAHAM D, SCHUSTER M et al.: Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA). In: Program and abstracts of Tandem Bone Marrow Transplantation Meetings. Orlando, FL, USA (2004):91.
32. DOWELL JA, SCHRANZ J, BARUCH A, FOSTER G: Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol. (2005) 45(12):1373-1382.
33. DOWELL J, STOGNIEW M, KRAUSE D: Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Presented at the 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, UK (2003):Poster 1222.
34. KRAUSE D, KILFOIL T, KILFOIL G, HENKEL T: Anidulafungin: pharmacokinetics in subjects with severe hepatic impairment. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology. San Diego, USA (2002):19 Abstract 1392.
35. BENJAMIN DK, DRISCOLL T, SIEBEL NL et al.: Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. (2006) 50(2):632-638.
36. PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2001) 45:471-479.
37. GROLL AH, MICKIENE D, PETRAITIENE R et al.: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agent Chemother. (2001) 45:2845-2855.
38. VAZQUEZ JA, SOBEL JD: Anidulafungin: a novel echinocandin. Clin. Infect. Dis. (2006) 43:215-222.
39. PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. (1999) 43:2148-2155.
40. PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1998) 42:2898-2905.
41. ROBERTS J, SCHOCK K, MARINO S, ANDRIOLE VT: Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. (2000) 44:3381-3388.
42. KRAUSE DS, SIMJEE AE, VAN RENSBURG C et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. (2004) 39:770-775.
43. ARATHOON EG, GOTUZZO E, NORIEGA LM, BERMAN RS, DINUBILE MJ, SABLE CA: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candiasis. Antimicrob. Agents Chemother. (2002) 46:451-457.
44. VAZQUEZ J, SCHRANZ JA, KRAUSE D et al.: Efficacy from a Phase II/3 study of anidulafungin (ANID) in patients (pts) with azole-refractory mucosal candidiasis (ARMC). In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology. Washington, DC, USA (2004):Poster 1040.
45. KRAUSE DS, GOLDSTEIN BP, WIBLE M et al.: A Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. (2004) 48:2021-2024.
46. REBOLI A, ROTSTEIN C, PAPPAS P et al.: Anidulafungin versus fluconazole for treatment of candidemia and invasive candidiasis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 15 - 19 December DC, USA (2005):Abstract 1040.
47. SCHRANZ J, KRAUSE D, HENKEL T: Lack of infusion-related adverse events with anidulafungin. In: Program and abstracts of the 15th Congress of the International Society for Human and Animal Mycology. San Antonio, USA (2003).
48. NO AUTHORS LISTED: Mycamine (micafungin) Package Insert. Deerfield, Ill; Astellas Pharma US, Inc. (2005).